STOCK TITAN

[144] Idexx Laboratories Inc SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144
Rhea-AI Filing Summary

Idexx Laboratories (IDXX) Form 144 notice: An insider intends to sell 2,187 shares of common stock, representing an aggregate market value of $1,415,700.21, on 08/22/2025 through Morgan Stanley Smith Barney LLC on NASDAQ. The shares were acquired the same day via stock option exercise and paid in cash. There were 80,004,694 shares outstanding reported for the issuer. The filer reports no sales in the prior three months. The filer certifies they are not aware of undisclosed material adverse information about the issuer.

Avviso Form 144 di Idexx Laboratories (IDXX): Un insider intende vendere 2.187 azioni ordinarie, per un valore complessivo di mercato di $1.415.700,21, il 22/08/2025 tramite Morgan Stanley Smith Barney LLC su NASDAQ. Le azioni sono state acquisite lo stesso giorno mediante esercizio di opzioni su azioni e saldate in contanti. L'emittente ha riportato 80.004.694 azioni in circolazione. Il dichiarante segnala nessuna vendita nei tre mesi precedenti e certifica di non essere a conoscenza di informazioni materiali sfavorevoli non divulgate riguardanti l'emittente.

Aviso Form 144 de Idexx Laboratories (IDXX): Un insider tiene la intención de vender 2.187 acciones ordinarias, con un valor de mercado agregado de $1.415.700,21, el 22/08/2025 a través de Morgan Stanley Smith Barney LLC en NASDAQ. Las acciones fueron adquiridas el mismo día mediante el ejercicio de opciones sobre acciones y pagadas en efectivo. La emisora declaró que había 80.004.694 acciones en circulación. El declarante informa no haber realizado ventas en los tres meses anteriores y certifica que no conoce información material adversa no divulgada sobre la emisora.

Idexx Laboratories(IDXX) Form 144 공시: 내부자가 2,187주 보통주를 매도할 의사를 밝혔으며, 총 시가액은 $1,415,700.212025-08-22에 Morgan Stanley Smith Barney LLC를 통해 NASDAQ에서 매도될 예정입니다. 해당 주식은 동일한 날 주식매수선택권 행사로 취득되었고 현금으로 지급되었습니다. 발행사는 80,004,694주의 유통주식을 보고했습니다. 제출인은 최근 3개월간의 매도 없음을 보고하며, 발행인에 대한 미공개 중대한 불리한 정보가 없음을 인증합니다.

Avis Form 144 d'Idexx Laboratories (IDXX) : Un initié a l'intention de vendre 2 187 actions ordinaires, représentant une valeur marchande totale de 1 415 700,21 $, le 22/08/2025 via Morgan Stanley Smith Barney LLC sur le NASDAQ. Les actions ont été acquises le même jour par exercice d'options sur actions et réglées en espèces. L'émetteur a déclaré 80 004 694 actions en circulation. Le déclarant indique aucune vente au cours des trois mois précédents et certifie ne pas être au courant d'informations défavorables matérielles non divulguées concernant l'émetteur.

Form-144-Mitteilung von Idexx Laboratories (IDXX): Ein Insider beabsichtigt, 2.187 Stammaktien zu verkaufen, mit einem aggregierten Marktwert von $1.415.700,21, am 22.08.2025 über Morgan Stanley Smith Barney LLC an der NASDAQ. Die Aktien wurden am selben Tag durch Ausübung von Aktienoptionen erworben und in Bargeld bezahlt. Für den Emittenten wurden 80.004.694 ausstehende Aktien gemeldet. Der Einreicher berichtet über keine Verkäufe in den vorangegangenen drei Monaten und bestätigt, dass ihm keine nicht offengelegten, wesentlichen nachteiligen Informationen zum Emittenten bekannt sind.

Positive
  • Complete disclosure of broker, number of shares, aggregate value, acquisition method, and payment type
  • No sales in prior three months, suggesting this is not part of ongoing heavy insider selling
  • Securities were acquired by option exercise and paid in cash, indicating standard compensation monetization
Negative
  • None.

Insights

TL;DR: Insider plans to sell a small block of shares acquired by option exercise; transaction appears routine and non-recurring.

The notice shows an insider executed options and intends to sell 2,187 shares valued at $1,415,700.21 through a broker on the Nasdaq exchange. The shares were acquired and are to be sold on the same date and were paid for in cash, which is consistent with option exercise followed by an immediate disposition. No other sales were reported in the prior three months, suggesting this is not part of a recurring disposal pattern. As a percentage of the outstanding share count (80,004,694), the block is immaterial from a dilution or control standpoint. The filing contains the required representation that no undisclosed material adverse information exists.

TL;DR: Disclosure aligns with Rule 144 procedural requirements; transaction raises no immediate governance concerns.

The Form 144 provides the broker name, size, market value, acquisition method, and payment type, meeting standard disclosure elements. The simultaneous acquisition by exercise and planned sale may reflect routine option monetization. The absence of aggregated sales in the prior three months reduces concern about concentrated insider selling. The filing includes the signature representation about material information, which is standard and important for compliance.

Avviso Form 144 di Idexx Laboratories (IDXX): Un insider intende vendere 2.187 azioni ordinarie, per un valore complessivo di mercato di $1.415.700,21, il 22/08/2025 tramite Morgan Stanley Smith Barney LLC su NASDAQ. Le azioni sono state acquisite lo stesso giorno mediante esercizio di opzioni su azioni e saldate in contanti. L'emittente ha riportato 80.004.694 azioni in circolazione. Il dichiarante segnala nessuna vendita nei tre mesi precedenti e certifica di non essere a conoscenza di informazioni materiali sfavorevoli non divulgate riguardanti l'emittente.

Aviso Form 144 de Idexx Laboratories (IDXX): Un insider tiene la intención de vender 2.187 acciones ordinarias, con un valor de mercado agregado de $1.415.700,21, el 22/08/2025 a través de Morgan Stanley Smith Barney LLC en NASDAQ. Las acciones fueron adquiridas el mismo día mediante el ejercicio de opciones sobre acciones y pagadas en efectivo. La emisora declaró que había 80.004.694 acciones en circulación. El declarante informa no haber realizado ventas en los tres meses anteriores y certifica que no conoce información material adversa no divulgada sobre la emisora.

Idexx Laboratories(IDXX) Form 144 공시: 내부자가 2,187주 보통주를 매도할 의사를 밝혔으며, 총 시가액은 $1,415,700.212025-08-22에 Morgan Stanley Smith Barney LLC를 통해 NASDAQ에서 매도될 예정입니다. 해당 주식은 동일한 날 주식매수선택권 행사로 취득되었고 현금으로 지급되었습니다. 발행사는 80,004,694주의 유통주식을 보고했습니다. 제출인은 최근 3개월간의 매도 없음을 보고하며, 발행인에 대한 미공개 중대한 불리한 정보가 없음을 인증합니다.

Avis Form 144 d'Idexx Laboratories (IDXX) : Un initié a l'intention de vendre 2 187 actions ordinaires, représentant une valeur marchande totale de 1 415 700,21 $, le 22/08/2025 via Morgan Stanley Smith Barney LLC sur le NASDAQ. Les actions ont été acquises le même jour par exercice d'options sur actions et réglées en espèces. L'émetteur a déclaré 80 004 694 actions en circulation. Le déclarant indique aucune vente au cours des trois mois précédents et certifie ne pas être au courant d'informations défavorables matérielles non divulguées concernant l'émetteur.

Form-144-Mitteilung von Idexx Laboratories (IDXX): Ein Insider beabsichtigt, 2.187 Stammaktien zu verkaufen, mit einem aggregierten Marktwert von $1.415.700,21, am 22.08.2025 über Morgan Stanley Smith Barney LLC an der NASDAQ. Die Aktien wurden am selben Tag durch Ausübung von Aktienoptionen erworben und in Bargeld bezahlt. Für den Emittenten wurden 80.004.694 ausstehende Aktien gemeldet. Der Einreicher berichtet über keine Verkäufe in den vorangegangenen drei Monaten und bestätigt, dass ihm keine nicht offengelegten, wesentlichen nachteiligen Informationen zum Emittenten bekannt sind.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the Form 144 for IDXX disclose?

It discloses an intended sale of 2,187 common shares valued at $1,415,700.21 to be executed on 08/22/2025 via Morgan Stanley Smith Barney LLC on NASDAQ.

How were the shares acquired according to the filing?

The filing states the shares were acquired on 08/22/2025 by a stock option exercise and paid for in cash.

Does the Form 144 show other recent insider sales?

The filing reports Nothing to Report under securities sold during the past three months.

How large is the sale relative to outstanding shares?

The issuer reported 80,004,694 shares outstanding; the 2,187-share block is immaterial as a percentage of that total.

Which broker will handle the sale?

The broker named is Morgan Stanley Smith Barney LLC Executive Financial Services located at 1 New York Plaza, New York.
IDEXX Laboratories

NASDAQ:IDXX

IDXX Rankings

IDXX Latest News

IDXX Latest SEC Filings

IDXX Stock Data

51.19B
79.45M
0.68%
97.51%
3.1%
Diagnostics & Research
In Vitro & in Vivo Diagnostic Substances
Link
United States
WESTBROOK